Jean-Charles Soria, MD, PhD, on Results of the Lux Lung 8 Clinical Trial
2015 European Cancer CongressJean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Jean-Charles Soria, MD, PhD, of Gustave Roussy, summarizes an important study: afatinib vs erlotinib in squamous cell carcinoma of the lung.
Shailender Bhatia, MD, of the Fred Hutchinson Cancer Center, discusses his paper on interleukin-12 DNA and regression of Merkel cell tumors (Abstract 504).
Milena Sant, MD, of Istituto Nazionale dei Tumori, discusses the question of whether Europe is doing better in cancer care since the 1990s (Abstract LBA1).
Matteo Lambertini, MD, Dana-Farber Cancer Institute, discusses the use of LHRH agonists during chemotherapy to suppress ovarian function as a way to preserve fertility in breast cancer patients (Abstract 1957).
As Chair of the ECC Local Organizing Committee, Christoph Zielinski, MD, of the Medical University Vienna - General Hospital, shares his thoughts on the important goals and presentations of the 2015 Congress.
Incoming ECCO President, Peter L. J. Naredi, MD, PhD, of the University of Gothenburg, discusses his upcoming year as the new ECCO President, his vision for the organization, and his views on cancer treatment today.